This study aims to investigate the safety and efficacy of transarterialchenmoembolization（TACE） combined with microspheres for unresectable hepatocellularcarcinoma(HCC).
Not Provided
Procedure: M-TACE
Lipiodol combined with microspheres
Inclusion Criteria:
1. 18≤Age<80 on day of signing informed consent.
2. Have histologically confirmed diagnosis or radiological diagnosis of HCC with at
least one >3cm targeted lesion.
3. Have Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease,
BCLC stage A disease but refuse a surgical or ablation therapy.
4. Have a Child-Pugh Class A/B（<7） liver score.
5. Have a performance status of 0 or 1 using the ECOG.
6. Have a predicted life expectancy of greater than 3 months.
Exclusion Criteria:
1. The targeted lesions have received TACE or other locoregional therapy within 3
months.
2. Tumor burden over 70% of the liver volume.
3. Lesions can not be measured by mRECIST.
4. Has a diagnosed additional malignancy.
5. Patients with Hb<9.0g/dL, WBC<1.0×10^9/L， TB>3mg/dL，ALT/AST>5 UL, ALB<2.8g/dL，
INR>2.3, Cr >2mg/mL or CCr<30mL/min.
6. Severe heart, lung or cerebral disease.
Department of Interventional Radiology, Zhongshan Hospital, Fudan University.
Shanghai, Shanghai, China
Not Provided